tnfa

TNFalpha-IN-S10 is an inhibitor of TNF-α.

Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Aurothiomalate sodium (Miochrysin) is a potent and selective inhibitor of oncogenic PKC-ι signaling. Aurothiomalate sodium is a potent thioredoxin reductase (TrxR) inhibitor. Aurothiomalate sodium exhibits potent anti-tumor activity.

Anti-TNFSF2/TNFa Antibody (hMAK195) is a human-derived antibody expressed in CHO cells, specifically targeting TNFSF2/TNFa. It features a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 145.06 kDa. For its isotype control, refer to HumanIgG1kappa, Isotype Control.

Anti-TNFSF2/TNFa Antibody is a human-derived antibody expressed in CHO cells, targeting TNFSF2/TNFa. It features a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 145 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.

R-7050 (TNF-α Antagonist III) is a tumor necrosis factor receptor (TNFR) antagonist that exhibits heightened selectivity for TNFα.

TNF-α-IN-1 is a TNF-α inhibitor.

TNF-α (31-45), human, is a peptide of tumor necrosis factor-α.

TNF-alpha-IN-1 (compound 202) is an orally active TNF-alpha inhibitor. This compound possesses anti-inflammatory properties and is applicable in research related to rheumatoid arthritis, psoriasis, and asthma.

TNF-α-IN-2 is an effective and orally active TNFα inhibitor that distorts the TNFα trimer upon binding, causing abnormal signal transduction when it binds to TNFR1, and can be used to study rheumatoid arthritis.

TNF-α antagonist is an exocyclic peptide that mimics the critical TNF-α recognition loop on TNF receptor I complex and, thus, prevents ligand interaction with the receptor. By blocking the TNF receptor ligand contact site, this peptide interferes with both activating receptor activator of NF-κB (RANK) and TNF-α's recruitment and activation of osteoclasts. TNF-α antagonist has been used to block bone resorption in the study of systemic bone loss in rheumatoid arthritis and inflammatory bone destruction.

TNF-α-IN-6 is an orally efficacious, allosteric inhibitor of TNFα (K_D = 6.8 nM).

Mca-(endo-1a-Dap(Dnp))-TNF-Alpha (-5 to +6) amide (human) is a peptide used as a fluorescence resonance energy transfer (FRET) based substrate for proteolytic activity assays, with cleavage-induced changes in fluorescence intensity indicating enzymatic activity [1].

TNF-α (10-36), human, is a potent pro-inflammatory cytokine involved in the acute phase stress response.

Human TNF alpha (46-65) peptide.

SIK-IN-3 (Compound 6B) is an inhibitor of salt-induced kinases (SIK), demonstrating inhibitory effects on SIK1, SIK2, and SIK3 with IC50 values of 0.1, 0.3, and 0.8 nM respectively. SIK-IN-1 inhibits TNFa release in human macrophages with an IC50 of 0.6 nM and stimulates LPS-induced IL-10 release with an EC50 of 3 nM.

LRH-1 modulator-1 is a potent modulator/agonist of LRH-1 (liver receptor homolog-1). LRH-1 modulator-1 induces the anti-inflammatory cytokine IL-10 and exhibits inhibition of the inflammatory cytokines IL-1b and TNFa. LRH-1 modulator-1 has anti-inflammatory activity in intestinal-like organs.

MF-592 is a potent and selective antagonists of the EP4 receptor. MF-592 demonstrated good functional potency (hEP4 IC50 = 3 nM) and potent inhibition of PGE2 modulated TNFa release in LPS stimulated human whole blood (hWB) (IC50 = 78nM). In addition, it showed an excellent oral pharmacokinetic (PK) profile and in vivo efficacy in a rat chronic adjuvant-induced-arthritis model (ED50 = 0.1 mg/kg/day).. MF-592 has a desirable overall preclinical profile that suggests it is suitable for further development.

Pegsunercept (PEG sTNF-RI), a pegylated monoclonal antibody, selectively binds to TNFA, incorporating a polyethylene glycol (pegol) moiety [1].

SIK-IN-1 (Compound 53) acts as a potent inhibitor of salt-inducible kinase (SIK), specifically targeting SIK1, SIK2, and SIK3 with IC50 values of 0.1, 0.4, and 1.5 nM, respectively. Additionally, it effectively suppresses TNFa release with an IC50 of 0.5 nM and enhances LPS-induced IL-10 release in human macrophages with an EC50 of 4 nM [1].

SIK-IN-2 (Compound 45) is a potent inhibitor of salt-inducible kinase (SIK), effectively targeting SIK1, SIK2, and SIK3 with IC50 values of 0.1, 0.2, and 0.4 nM, respectively. Additionally, it suppresses TNFa release with an IC50 of 0.5 nM and promotes LPS-induced IL-10 release with an EC50 of 2 nM in human macrophages [1].

AQX-016A is an orally active and potent SHIP1 agonist. It is a structural analog of pelorol and is three times more potent than the marine natural product pelorol at the same molar concentration. AQX-016A can activate recombinant SHIP1 enzyme in vitro and stimulate SHIP1 activity. It also inhibits the PI3K pathway and TNFa production, making it useful for various inflammatory diseases research [1] [2].

ESBA-105 is a human-derived antibody expressed in CHO cells, specifically targeting TNFSF2/TNFa. It features a heavy chain of huIgG1 type and a light chain of huκ type, with an estimated molecular weight (MW) of 145.14 kDa. For isotype controls, HumanIgG1kappa, Isotype Control can be consulted.

CMAB008 is a human-derived antibody expressed in CHO cells, targeting TNFSF2/TNFa. It features a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 145 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.

Senlizumab is a human-derived antibody expressed in CHO cells, targeting TNFSF2/TNFa. It features a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.9 kDa. For its isotype control, refer to HumanIgG4kappa, Isotype Control.